TheraDoc

The core engine evaluates alert logic that the hospital's own pharmacists and infection preventionists write, continuously against incoming clinical data, and Premier makes no artificial intelligence or machine learning claim for it.

A learned component is present all the same: Premier's own material states that TheraDoc integrates InsightRX Nova, a cloud based precision dosing platform whose population pharmacokinetic models are updated on a patient's measured drug levels, which is a model estimated from data. It is a feature layer on a product whose value stands without it, since the surveillance, stewardship and reporting functions run on rules. A rules engine described as a rules engine is more useful to a buyer than one dressed up as something else, and the one model inside is licensed from another company rather than built by Premier.

Alerts reach a clinical pharmacist or an infection preventionist who investigates and acts, and the platform never touches an order. The structural difference from a model driven product is that the customer authors the logic: alert rules are written by the hospital's own clinicians rather than supplied by the vendor, so the institution controls both what fires and what threshold fires it, and there is no vendor decision to defer to. The corresponding weakness is also local.

A rule written badly, or left unrevised as practice changes, produces alert fatigue, and Premier publishes no alert burden figure, no guidance on rule review cadence and no tooling described for identifying rules that fire without ever changing care.

When the hospital's pharmacists author the alert logic themselves, every criterion behind every alert is readable by the institution that will act on it, and a pharmacist can answer why an alert fired by opening the rule. The one learned component is named: Premier states that TheraDoc integrates InsightRX Nova for precision dosing. Two things are missing.

Premier's material describes nothing of that dosing component's models, versions or updates, so the one part of the product that learns is also the part Premier leaves undescribed. And Premier publishes no library documentation, no description of the shipped starter rule set and no account of how supplied rules were validated before distribution.

The model provider is named. Premier states that TheraDoc integrates InsightRX Nova, InsightRX's cloud based precision dosing platform, for individualized antibiotic dosing, and the rest of the alerting layer is a rules engine the hospital configures, so the institution can read what the system evaluates without needing the vendor to describe it.

The terms around that supplier relationship are not published: how data passes between TheraDoc and InsightRX's platform, where InsightRX processes it, and what either party may retain or reuse. No hosting arrangement or subprocessor list is published for TheraDoc itself. The parent relationship is where the substantive question sits.

The platform consumes continuous live feeds of laboratory, microbiology, pharmacy, admission and medication data across an entire hospital, and Premier operates as a healthcare data business alongside it; Premier's privacy notice says that when it receives protected health information as a business associate it adheres to the agreement with the provider, and says nothing more about secondary use. Whether surveillance data stays scoped to the hospital's own alerting or contributes to Premier's wider analytics is the material term.

The market position is long established and the published evidence is customer reported. Premier's product page claims a 40 percent cut in daily surveillance time, a 33 percent increase in antibiotic related pharmacist interventions and about $29,000 saved by preventing four Clostridium difficile cases in a year at HSHS St. Elizabeth's Hospital, and an estimated $420,000 in annualized savings at Billings Clinic. None comes with a method, a denominator or a comparison.

No peer reviewed outcome study, controlled evaluation or published data on alert validity, override rate or the share of alerts that changed care is published. Twenty five years of continuous use across a large installed base says something about workflow fit and reliability, not about benefit.

The platform consumes continuous live feeds of laboratory, microbiology, pharmacy, admission and medication data across an entire hospital, a broad clinical footprint, and the parent operates a healthcare data business alongside it. What is published is general assurance: the product page claims data security and HIPAA compliance, and Premier's privacy notice says patient data received as a business associate is handled under the provider's agreement.

No retention schedule, de identification practice or statement about training or secondary use is published for surveillance data, including whether it contributes to Premier's wider analytics or reaches InsightRX's dosing platform beyond the patient being dosed. Nothing is published on safety engineering either: how a rule that has gone wrong, or a wrong dose from the integrated dosing tool, is detected and corrected. Given the parent's scale as a data company and its move to private equity ownership, the secondary use question deserves a direct answer.

Business associate status is stated, and the only privacy document published covers everything except the patient data. Premier's privacy notice (updated April 2026) says that when Premier receives protected health information performing services for health care providers it acts as a business associate and adheres to the agreement it has with the provider, and it expressly excludes that processing from its own scope.

The TheraDoc product page claims HIPAA compliance alongside ONC certification and third party vulnerability assessments. No agreement text, tier, breach notification timeline, subcontractor terms or data return obligations are published, and nothing explains which Premier entity signs for TheraDoc after the parent's change of ownership.

The product page names three things: ONC Health IT certification, third party vulnerability assessments and HIPAA compliance. The ONC certification is a real external review with a public artifact: Premier's certifications page lists the criteria TheraDoc is certified against, which include the privacy and security criteria for authentication, auditable events, audit reports, end user device encryption, credential encryption and multi factor authentication, alongside public health reporting to the national surveillance network.

That certification tests what the software can do, not how Premier operates it. The third party vulnerability assessments are named with no cadence or date. No SOC 2 report, HITRUST certification, ISO 27001, trust center or vulnerability disclosure program is published for TheraDoc or for Premier as its operator, so the controls have outside checks and no attestation of how they are run.

No device clearance is claimed and none would be expected for the surveillance functions, since the product surfaces alerts for a clinician to investigate rather than computing a therapeutic quantity, which sits within the statutory exclusion for non device clinical decision support. The product page invites one confusion.

ONC Health IT certification is administered under an entirely different program from device regulation and assesses interoperability, data standards and security functions rather than clinical safety or efficacy, so the certification on the page does not mean any regulator has assessed whether the alerts are clinically correct.

The integrated InsightRX dosing tool raises the sharper question, since computing a dose is the function regulators have treated as a device function for some dosing software; InsightRX states that its platform is not a medical device in the United States, and Premier publishes no position of its own on the combined product.

Premier publishes no performance reporting by any patient characteristic, no bias assessment, no rule validation methodology and no post deployment monitoring statement for TheraDoc. The exposure in a rules driven system is different from a model driven one and is not smaller.

Rules encode the assumptions of whoever wrote them, including thresholds drawn from populations that may not resemble the patients being screened, and there is no drift monitoring concept for rules, so a rule that has quietly become wrong as practice or resistance patterns changed keeps firing with institutional authority behind it.

The integrated dosing component is the one learned model, and its supplier, InsightRX, publishes its own analyses of how its models perform by body mass; Premier does not cite or carry them for TheraDoc. The standing ask is what detects a rule that has gone stale and who owns that review, and whether Premier will publish or reference the dosing model's performance across patient groups.

The design allocates responsibility plainly. The hospital's own pharmacists author the alert logic, so every criterion behind every alert is readable by the institution that will act on it. Alerts go to a pharmacist or infection preventionist who decides, and the platform never touches an order, so human review always comes before commit. Two gaps sit against that.

The shipped starter rule set is undocumented, with no account of how supplied rules were validated before distribution, so the rules a hospital inherits on day one carry the vendor's judgment without the vendor's evidence. And Premier publishes no accuracy figure for the integrated InsightRX dosing component and cites no study of it, so the one part of the product that learns has no published error rate to hold Premier to. No warranty, indemnity or remediation commitment is published.

The platform is designed to sit across whatever record system a hospital runs, consuming live laboratory, microbiology, pharmacy and admission feeds and returning alerts and dashboards, and Premier's product page says it connects directly to the hospital's EHR.

Standards conformance has an external check: TheraDoc is ONC certified for public health reporting to the national surveillance network, and the deployments behind it are named, including BayCare, Billings Clinic and HSHS St. Elizabeth's Hospital, with federal medical centers reached through a government reseller.

Beyond that, no record system is named as an integration partner, no FHIR conformance statement, marketplace listing or public interface documentation is published, and alert delivery back into the clinician's workflow is not described technically.

The product is delivered as software as a service on Premier's technology platform, the model it has used since the acquisition, to United States hospitals, so the location is implied rather than committed. Premier publishes no hosting provider, cloud region, data residency commitment or on premise option for TheraDoc, and no description of what happens to surveillance coverage during an outage, which for a continuous alerting system is a clinical question rather than an availability one.

Premier describes the integrated InsightRX Nova tool as InsightRX's cloud based platform, and where it processes dosing data is not stated. The ownership change matters here too, since a take private transaction is often followed by infrastructure consolidation, and nothing published says whether hosting arrangements are contractually fixed.

Premier publishes no price, unit, pricing basis, contract shape or implementation fee for TheraDoc; the route in is a demo request. Two commercial dynamics bear on renewal. The parent completed a take private transaction valued at $2.6 billion after reporting an eleven percent revenue decline in fiscal 2025, and private equity ownership typically brings a review of product pricing and portfolio scope, so renewal terms may not carry over unchanged.

And the same parent owns a separate point of care decision support product and sells the InsightRX integration alongside TheraDoc, which creates an obvious bundling path; nothing published says what is priced separately today, including the dosing tool, or what may be packaged together later.

Functional coverage is broad: infection prevention with mandatory reporting to the national surveillance network, antimicrobial stewardship including de escalation and organism to therapy mismatch alerting, pharmacy surveillance for adverse drug events, anticoagulation monitoring and antibiogram reporting, so a single platform serves the pharmacy department, the infection prevention team and quality reporting.

Premier's product page states the platform is built for hospitals and long term care and proven across acute and post acute settings, and the named customer results come from acute hospitals. Institutional coverage extends across a large installed base and into federal medical centers through a government reseller. The post acute claim, though, has no named deployment or result behind it, no ambulatory coverage is described, and the footprint is United States only.